Bio News
Japan’s Otsuka and U.S.-based Ionis Pharmaceuticals said the investigational amyotrophic lateral sclerosis (ALS) treatment ulefnersen met its primary endpoint in a phase 3 clinical trial.
The FUSION trial enrolled 89 patients with rare ALS caused by mutations in the FUS gene.
Otsuka plans to work closely with health authorities to pursue accelerated approval of ulefnersen.
BIOBOOK TEAM
biobookmedia@biobook.co.krParagon Spin-Off Velaris Goes Public Through Reverse Merger With Alaunos
Syndax halts development of Niktimvo for pulmonary fibrosis; shares plunge 17%
BioNTech’s mRNA Cancer Vaccine Misses Primary Endpoint for Progression-Free Survival in Phase 3 Trial
Roche Signs $1.6 Billion Deal With China’s Rona for ALK7 Obesity Drug
Formycon and Zydus’ Keytruda Biosimilar Is First to Be Accepted for FDA Review
Pfizer Signs $500 Million Protein Degrader Deal With Enodia
